Programmed cell death-1 (PD-1) is associated with cancer immune checkpoint mechanisms, and anti-PD-1 antibodies have been used widely for immunotherapy in various types of cancer, including HCC [13,14]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.